These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38845393)

  • 21. Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).
    Gaudet D; Durst R; Lepor N; Bakker-Arkema R; Bisgaier C; Masson L; Golden L; Kastelein JJ; Hegele RA; Stein E
    Am J Cardiol; 2019 Dec; 124(12):1876-1880. PubMed ID: 31685212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Kastelein JJP; Rubba P; Duell PB; Koseki M; Stroes E; Ali S; Banerjee P; Chan KC; Khilla N; McGinniss J; Pordy R; Zhang Y; Gaudet D
    JACC Adv; 2023 Nov; 2(9):100648. PubMed ID: 38938723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marked plaque regression in homozygous familial hypercholesterolemia.
    Reeskamp LF; Nurmohamed NS; Bom MJ; Planken RN; Driessen RS; van Diemen PA; Luirink IK; Groothoff JW; Kuipers IM; Knaapen P; Stroes ESG; Wiegman A; Hovingh GK
    Atherosclerosis; 2021 Jun; 327():13-17. PubMed ID: 34004483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab.
    Shamsudeen I; McCrindle BW; Hegele RA
    JCEM Case Rep; 2023 May; 1(3):luad058. PubMed ID: 37305647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Existing and emerging therapies for the treatment of familial hypercholesterolemia.
    Rosenson RS
    J Lipid Res; 2021; 62():100060. PubMed ID: 33716107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
    Stefanutti C
    Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
    Blom DJ; Harada-Shiba M; Rubba P; Gaudet D; Kastelein JJP; Charng MJ; Pordy R; Donahue S; Ali S; Dong Y; Khilla N; Banerjee P; Baccara-Dinet M; Rosenson RS
    J Am Coll Cardiol; 2020 Jul; 76(2):131-142. PubMed ID: 32646561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia.
    Gu J; Kuznik A; Quon P; Chauhan A; Sravya TS; Raal FJ
    Eur J Prev Cardiol; 2023 Nov; 30(17):1874-1880. PubMed ID: 37314419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evinacumab for the treatment of homozygous familial hypercholesterolemia.
    Gao Y; Zhang B; Yang J
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):139-145. PubMed ID: 35220876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.
    Reeskamp LF; Millar JS; Wu L; Jansen H; van Harskamp D; Schierbeek H; Gipe DA; Rader DJ; Dallinga-Thie GM; Hovingh GK; Cuchel M
    Arterioscler Thromb Vasc Biol; 2021 May; 41(5):1753-1759. PubMed ID: 33691480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
    Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
    Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evinacumab in Patients with Refractory Hypercholesterolemia.
    Rosenson RS; Burgess LJ; Ebenbichler CF; Baum SJ; Stroes ESG; Ali S; Khilla N; Hamlin R; Pordy R; Dong Y; Son V; Gaudet D
    N Engl J Med; 2020 Dec; 383(24):2307-2319. PubMed ID: 33196153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
    Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
    Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia.
    Pu X; Sale M; Yang F; Zhang Y; Davis JD; Al-Huniti N
    CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1412-1421. PubMed ID: 34585515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.
    Stein EA; Dann EJ; Wiegman A; Skovby F; Gaudet D; Sokal E; Charng MJ; Mohamed M; Luirink I; Raichlen JS; Sundén M; Carlsson SC; Raal FJ; Kastelein JJP
    J Am Coll Cardiol; 2017 Aug; 70(9):1162-1170. PubMed ID: 28838366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary.
    Gu J; Gupta RN; Cheng H; Xu Y; Raal FJ
    Eur J Prev Cardiol; 2024 Apr; ():. PubMed ID: 38640433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evinacumab to treat hypercholesterolemia.
    Engler C; Ebenbichler C
    Drugs Today (Barc); 2021 Oct; 57(10):607-619. PubMed ID: 34713869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia.
    Duell PB; Warden BA
    Ther Apher Dial; 2022 Dec; 26 Suppl 1():12-17. PubMed ID: 36468314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.